Sign up Australia
Proactive Investors - Run By Investors For Investors

The Hydroponics Company positions itself to take advantage of Australian market

Changes to regulations in Australia have opened the door for cannabis breeders.
Picture of cannabis plant
The vertically integrated model aims to target multiple medicinal cannabis markets

The Hydroponics Company Ltd (ASX:THC) continues to build its capabilities to drive growth within the existing regulatory and clinical frameworks that exist in Australia.

Recruitment for the required skillsets to build the Australian business is underway.

Management is engaging personnel who can assist in research and development, growing and manufacturing, importation, clinical trials and promoting product demand.

There have also been management changes at the company with Dr Andrew Beehag, former head of Canndeo finishing in March 2018, and the experienced Steven Xu recently appointed as a director.

New engagements at an operational level and management changes will improve the group’s capabilities, driving growth within the existing regulatory and clinical frameworks that exist in Australia.

Well positioned to take advantage of changes in export rules

With more than 17 years of cannabis sativa breeding, variety selection and growth management, The Hydroponics Company is actively developing plant breeding technology.

This is aimed at multiple markets for high purity cannabidiol, a new class of medicinal product that can be used to target dementia, epilepsy and other neurological disorders.

The Hydroponics Company is well-positioned to take advantage of changes in export rules recently announced by the Federal Government.

This development resulted in the company’s shares increasing by circa 50% in January, and they touched a one-month intraday high of $1.12 less than a fortnight ago.

Join our Crypto, Blockchain and Cannabis Telegram group here
View full THC profile View Profile

The Hydroponics Company Ltd Timeline

Related Articles

cannabis leaf and green tablets
October 30 2018
The company will now proceed with stage II of the human clinical trial.
October 10 2018
Management behind ICC International Cannabis Corp has a clear buy, build and sell strategy
August 28 2018
Tidal Royalty provides capital to help grow licenced US cannabis firms in exchange for receiving a percentage of future top-line revenues.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use